ABIVAX Société Anonyme (AAVXF)
OTCMKTS · Delayed Price · Currency is USD
120.85
0.00 (0.00%)
Feb 11, 2026, 4:00 PM EST
ABIVAX Société Anonyme Employees
ABIVAX Société Anonyme had 67 employees as of September 30, 2025. The number of employees increased by 5 or 8.06% compared to the same quarter last year.
Employees
67
Change
5
Growth
8.06%
Revenue / Employee
$93,006
Profits / Employee
-$5,140,086
Market Cap
9.07B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2025 | 67 | 5 | 8.06% | 67 | 0 |
| Jun 30, 2025 | 69 | 7 | 11.29% | 69 | 0 |
| Mar 31, 2025 | 69 | 8 | 13.11% | 69 | 0 |
| Jun 30, 2024 | 62 | - | - | 62 | 0 |
| Dec 31, 2023 | 61 | 37 | 154.17% | 61 | 0 |
| Dec 31, 2022 | 24 | 0 | - | 24 | 0 |
| Dec 31, 2021 | 24 | -3 | -11.11% | 24 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Silence Therapeutics | 116 |
| Vaxart | 105 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Nuo Therapeutics | 9 |
| ZIVO Bioscience | 7 |
| Vicapsys Life Sciences | 2 |
ABIVAX Société Anonyme News
- 12 days ago - Better Long-Term Buy: This Emerging Player or the Industry Leader? - The Motley Fool
- 13 days ago - Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance - Seeking Alpha
- 22 days ago - Eli Lilly (LLY) Denies Acquisition Talks with Abivax (ABVX) - GuruFocus
- 22 days ago - Abivax CEO responds to Lilly acquisition rumors - Seeking Alpha
- 22 days ago - Abivax CEO dismisses 'noise' around rumored Eli Lilly bid - Reuters
- 23 days ago - Prediction: This Healthcare Stock Could Soar by 72% in 2026 - The Motley Fool
- 4 weeks ago - Abivax's Options: A Look at What the Big Money is Thinking - Benzinga
- 4 weeks ago - Abivax: Don't Just Buy The Rumor, Buy The Fundamentals - Seeking Alpha